MA30529B1 - Formes galeniques solides du valsartan, de l'amlodipine et de l'hydrochlorothiazide et leur methode de fabrication - Google Patents

Formes galeniques solides du valsartan, de l'amlodipine et de l'hydrochlorothiazide et leur methode de fabrication

Info

Publication number
MA30529B1
MA30529B1 MA31506A MA31506A MA30529B1 MA 30529 B1 MA30529 B1 MA 30529B1 MA 31506 A MA31506 A MA 31506A MA 31506 A MA31506 A MA 31506A MA 30529 B1 MA30529 B1 MA 30529B1
Authority
MA
Morocco
Prior art keywords
valsartan
hydrochlorothiazide
amlodipine
manufacturing
galenic forms
Prior art date
Application number
MA31506A
Other languages
English (en)
Inventor
Yu Cao
Yatindra Joshi
Ping Li
Madhusudhan Pudipeddi
Alan Edward Royce
Robert Frank Wagner
Jiahao Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38662673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30529(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30529B1 publication Critical patent/MA30529B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur les formes galéniques solides monocouches, bicouches et tricouches d'une combinaison de valsartan, d'amlodipine et d'hydrochlorothiazide.
MA31506A 2006-06-27 2008-12-24 Formes galeniques solides du valsartan, de l'amlodipine et de l'hydrochlorothiazide et leur methode de fabrication MA30529B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80588306P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
MA30529B1 true MA30529B1 (fr) 2009-06-01

Family

ID=38662673

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31506A MA30529B1 (fr) 2006-06-27 2008-12-24 Formes galeniques solides du valsartan, de l'amlodipine et de l'hydrochlorothiazide et leur methode de fabrication

Country Status (22)

Country Link
US (2) US20100003321A1 (fr)
EP (1) EP2037893A2 (fr)
JP (1) JP2009542709A (fr)
KR (1) KR20090021191A (fr)
CN (2) CN103169711A (fr)
AR (1) AR061627A1 (fr)
AU (1) AU2007265138A1 (fr)
BR (1) BRPI0713785A2 (fr)
CA (1) CA2654986A1 (fr)
CL (1) CL2007001870A1 (fr)
EC (1) ECSP088987A (fr)
IL (1) IL195797A0 (fr)
MA (1) MA30529B1 (fr)
MX (1) MX2008016532A (fr)
NO (1) NO20090314L (fr)
NZ (1) NZ573295A (fr)
PE (2) PE20080991A1 (fr)
RU (1) RU2449786C2 (fr)
TN (1) TNSN08538A1 (fr)
TW (1) TW200808379A (fr)
WO (1) WO2008002905A2 (fr)
ZA (1) ZA200810053B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3239B1 (ar) 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
AP2011005795A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan
JP5758900B2 (ja) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
CN102091069A (zh) * 2009-12-11 2011-06-15 浙江华海药业股份有限公司 缬沙坦和氨氯地平的复方制剂及其制备方法
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
CN101829111B (zh) * 2010-05-23 2014-12-17 浙江华海药业股份有限公司 含有缬沙坦的固体制剂及其制备方法
CN102716132B (zh) * 2011-03-29 2015-09-30 石药集团中奇制药技术（石家庄）有限公司 复方氨氯地平/缬沙坦/氢氯噻嗪片及其制备方法
MX2014007933A (es) * 2011-12-26 2014-07-30 Novartis Ag Comprimidos y agentes recubiertos en seco.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102614190A (zh) * 2012-04-17 2012-08-01 北京哈三联科技股份有限公司 含有缬沙坦、氨氯地平和氢氯噻嗪的片剂及其制备方法
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
MX358211B (es) 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
CN103655580B (zh) * 2012-08-28 2017-12-01 海南中济医药科技有限公司 一种含有缬沙坦、苯磺酸氨氯地平和氢氯噻嗪的药物组合物及其制备方法
TW201427720A (zh) * 2012-10-12 2014-07-16 Ajinomoto Kk 含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑之製造方法
CN102846625A (zh) * 2012-10-18 2013-01-02 海口华仕联医药科技有限公司 一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
FI4000608T3 (fi) 2013-04-18 2026-01-21 Boehringer Ingelheim Int Farmaseuttinen koostumus, menetelmä hoitamiseksi ja sen käyttöjä
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
CN105106962A (zh) * 2015-08-29 2015-12-02 西安力邦肇新生物科技有限公司 一种复方降压制剂及其应用
JP6411662B2 (ja) * 2016-05-30 2018-10-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 固定容量配合剤
KR20250097990A (ko) 2016-11-10 2025-06-30 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
KR102568472B1 (ko) 2017-02-27 2023-08-18 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
WO2019008485A1 (fr) * 2017-07-06 2019-01-10 Mankind Pharma Ltd Composition pharmaceutique à dose fixe à base de valsartan et de sacubitril
KR20260037123A (ko) 2017-11-30 2026-03-17 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
WO2022132067A1 (fr) * 2020-12-18 2022-06-23 Santa Farma Ilac Sanayii A.S. Compositions de comprimés bicouches stables
CN113171352A (zh) * 2021-04-15 2021-07-27 海南锦瑞制药有限公司 一种沙坦类降压复方制剂的制备方法
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
US20040087484A1 (en) * 2000-12-01 2004-05-06 Sahota Pritam Singh Combination of organic compounds
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CN101352421A (zh) * 2002-01-16 2009-01-28 贝林格尔英格海姆法玛两合公司 一种制备基本上非结晶形式的替米沙坦的方法
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR100580168B1 (ko) 2003-03-21 2006-05-16 삼성전자주식회사 다중 홈 에이전트 제어장치 및 방법
US20050187262A1 (en) 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
ES2385832T3 (es) 2004-05-21 2012-08-01 Accu-Break Technologies, Inc. Comprimidos farmacéuticos que presentan un segmento relativamente inactivo
CN103083318A (zh) * 2004-11-05 2013-05-08 贝林格尔.英格海姆国际有限公司 包含替米沙坦和氨氯地平的双层片剂
CN100389830C (zh) * 2005-05-08 2008-05-28 广州市施柏医药科技有限公司 一种治疗高血压的药物组合物

Also Published As

Publication number Publication date
TW200808379A (en) 2008-02-16
CN101478956B (zh) 2013-03-20
NZ573295A (en) 2012-01-12
RU2449786C2 (ru) 2012-05-10
MX2008016532A (es) 2009-01-19
JP2009542709A (ja) 2009-12-03
HK1133818A1 (en) 2010-04-09
IL195797A0 (en) 2009-09-01
US8475839B2 (en) 2013-07-02
US20120164218A1 (en) 2012-06-28
NO20090314L (no) 2009-01-26
ECSP088987A (es) 2009-01-30
CN103169711A (zh) 2013-06-26
TNSN08538A1 (en) 2010-04-14
US20100003321A1 (en) 2010-01-07
PE20120542A1 (es) 2012-05-14
WO2008002905A3 (fr) 2008-12-11
CN101478956A (zh) 2009-07-08
WO2008002905A2 (fr) 2008-01-03
CA2654986A1 (fr) 2008-01-03
ZA200810053B (en) 2009-11-25
BRPI0713785A2 (pt) 2012-10-30
EP2037893A2 (fr) 2009-03-25
AU2007265138A1 (en) 2008-01-03
RU2009102273A (ru) 2010-08-10
KR20090021191A (ko) 2009-02-27
PE20080991A1 (es) 2008-09-05
AR061627A1 (es) 2008-09-10
CL2007001870A1 (es) 2008-06-13

Similar Documents

Publication Publication Date Title
MA30529B1 (fr) Formes galeniques solides du valsartan, de l'amlodipine et de l'hydrochlorothiazide et leur methode de fabrication
BRPI0716893A2 (pt) Forma de dosagem sólida de olmesartan medoxomila e anlodipina
EP2019825A4 (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
BRPI0616703A2 (pt) forma de dosagem farmacêutica
TNSN08071A1 (en) Solid dosage forms of valsartan and amlodipine and method of making the same
EP2220046A4 (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP2220095A4 (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP2220084A4 (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
CL2007003645A1 (es) Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria.
DE112006002043A5 (de) Verbesserte Keilnutverbindung
DK1968990T3 (da) Vandopløselig benzoazepinforbindelse og farmaceutisk sammensætning deraf
ZA200705852B (en) 2-OXO-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines used as CGRP antagonists
BRPI0614413A2 (pt) composto, e, composição farmacêutica
BRPI0614412A2 (pt) composto, e, composição farmacêutica
ZA200711023B (en) Metal salts of 2'-(1h-tetrazol-5-yl)-1.1'-bipheny-4-carboxaldehyde
GB201018110D0 (en) Solid dosage form of olmesartan medoxomil, amiodipine and hydrochlorothiazide
FR2898473B1 (fr) Ensemble modulaire pour la construction notamment de columbarium
ES1060422Y (es) Almohada terapeutica de cascara de alforfon.
FI20055317A0 (fi) Kloorin kerrostumisen estäminen liejukattiloissa
UA13071S (uk) Упаковка фармацевтичного препарату «повадин»
FI20050212A0 (fi) Modifioidusti vapauttava annosmuoto
HK1128001A (en) Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
UA12201S (uk) Комплект упаковок для фармацевтичного препарату «fanhdi»
ITRC20060008A1 (it) "combustibile solido ecologico"